Once-weekly Byetta better than Lantus in Phase III trial
This article was originally published in Scrip
Lilly/Amylin's once-weekly version of the twice-daily injectable diabetes drug Byetta (exenatide) has been shown in a head-to-head Phase III trial, DURATION-3, to provide slightly improved glucose control, weight loss as opposed to weight gain, and a lower incidence of hypoglycaemia compared with Sanofi-Aventis's once-daily insulin analogue Lantus (insulin glargine), which could bode will for the drug's approval.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.